Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TACR1 | P25103 | 2/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4545487 | 1.00 | CA1 (0.53) | CA1CA2CA7CA9TSHR | |
| SCHEMBL149042 | 1.00 | CA1 (0.53) | CA1CA2CA7CA9TSHR | |
| SCHEMBL3883464 | 0.91 | TSHR (0.47) | CA1CA2CA7CA9TSHR | |
| SCHEMBL13839552 | 0.91 | TSHR (0.47) | CA1CA2CA7CA9TSHR | |
| SCHEMBL14453899 | 0.88 | TSHR (0.61) | CA1CA2CA7CA9TSHR | |
| SCHEMBL1195445 | 0.85 | CA1 (0.50) | CA1CA2CA7CA9TSHR | |
| SCHEMBL12361734 | 0.83 | AGXT (0.44) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL12519871 | 0.82 | TSHR (0.54) | CA1CA2CA7CA9TSHR | |
| SCHEMBL10052366 | 0.82 | TSHR (0.54) | CA1CA2CA7CA9TSHR | |
| SCHEMBL13003073 | 0.82 | TSHR (0.54) | CA1CA2CA7CA9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135586-A1 | THIOENO[3,2-B] PYRIDIN-7-AMINE COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | PTC THERAPEUTICS, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-20130196987-A1 | MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS | EISAI CO., LTD. (JP) | 2013-08-01 | — | — | US | disclosed |
| US-8329742-B2 | Macrocyclic compounds useful as pharmaceuticals | EISAI CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20110144101-A1 | MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS | EISAI CO., LTD. (JP) | 2011-06-16 | — | — | US | disclosed |
| EP-1984377-A2 | INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH | Signal Pharmaceuticals LLC (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20080004271-A1 | Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith | MCKENNA JEFFREY M | 2008-01-03 | — | — | US | disclosed |
| WO-2007084560-A2 | INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-07-26 | — | — | WO | disclosed |
| EP-1165076-A4 | 6-AZAINDOLE COMPOUNDS AS ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO INC (US) | 2002-05-15 | — | — | EP | disclosed |
| EP-1165075-A4 | 6-AZAINDOLE COMPOUNDS AS ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO INC (US) | 2002-04-10 | — | — | EP | disclosed |
| EP-1165075-A1 | 6-AZAINDOLE COMPOUNDS AS ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | Merck & Co., Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| US-6077847-A | ADMINISTERING A SUBSTITUTED INDOLE COMPOUND TO THE PATIENTS FOR THE TREATMENT OF A VARIETY OF SEX-HORMONE RELATED AND OTHER CONDITIONS IN BOTH MEN AND WOMEN | MERCK & CO., INC. (US) | 2000-06-20 | — | — | US | disclosed |
| US-6025366-A | Antagonists of gonadotropin releasing hormone | MERCK & CO., INC. (US) | 2000-02-15 | — | — | US | disclosed |
| US-5998432-A | SEXUAL DISORDERS | MERCK & CO., INC. (US) | 1999-12-07 | — | — | US | disclosed |
| US-5985892-A | USEFUL FOR THE TREATMENT OF A VARIETY OF SEX-HORMONE RELATED AND OTHER CONDITIONS IN BOTH MEN AND WOMEN; PREVENTING PREGNANCY; TREATING LUPUS ERYTHEMATOSIS, IRRITABLE BOWEL SYNDROME, PREMENSTRUAL SYNDROME, HIRSUTISM, SHORT STATURE OR A | MERCK & CO., LTD. (US) | 1999-11-16 | — | — | US | disclosed |
| WO-1999051234-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1999-10-14 | — | — | WO | disclosed |
| WO-1999051233-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1999-10-14 | — | — | WO | disclosed |
| WO-1999051231-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1999-10-14 | — | — | WO | disclosed |
| WO-1999051596-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1999-10-14 | — | — | WO | disclosed |
| WO-1999051595-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1999-10-14 | — | — | WO | disclosed |
| US-5684152-A | CARBOXY DERIVATIVES FOR TREATMENT OF CARDIOVASCULAR DISORDERS | MERCK & CO., INC. (US) | 1997-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135586-A1 | THIOENO[3,2-B] PYRIDIN-7-AMINE COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | SF3B5, SF3B2, SF3B1 | CA1 4838/4885CA2 4657/4885CA7 4739/4885 |
| US-20110144101-A1 | MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS | FLT1, TBXA2R, VEGFA | CA1 3596/4885CA2 3153/4885CA7 2387/4885 |
| US-20080004271-A1 | Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith | PDE4A, PDE4B, BRAF | CA1 233/4885CA2 893/4885CA7 598/4885 |
| US-20130196987-A1 | MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS | FLT4, VEGFA, FLT1 | CA1 3237/4885CA2 2388/4885CA7 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.